A Phase 2 interventional study of Pacritinib in Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis and Post- Essential Thrombocythemia Myelofibrosis, sponsored by CTI BioPharma. Completed at 62 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-01.
Sponsored by CTI BioPharma (part of Swedish Orphan Biovitrum) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing pacritinib in Primary Myelofibrosis — 6 open to participants now, 8 under way, 1 of them phase 3. pacritinib · Primary Myelofibrosis.
Among the 18 studies testing pacritinib in Primary Myelofibrosis, this one is the 4th largest by enrollment, is one of 3 that started in 2017, is one of 8 in phase 2, and was the 13th registered.
627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.
Browse Primary Myelofibrosis studies →6 of the 18 studies testing pacritinib in Primary Myelofibrosis are open now, in 2 countries. Recruiting first, the newest first:
John Mascarenhas · Sites in United States
Ages 18+
Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas · Sites in Spain
Ages 18+
University of Kansas Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
Fox Chase Cancer Center · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
By country, each count listing its studies:
pacritinib: first FDA approval 2022 (VONJO). What it is approved for, and how studies give it, is on its page →
Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 3
First in 2008; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 165 is above the median of 43 across 491 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 35 across the 18 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under CTI BioPharma, one of the names counted as Swedish Orphan Biovitrum. Under that name alone:
CTI BioPharma is the lead sponsor of 38 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.
Swedish Orphan Biovitrum has 7 studies filed under Primary Myelofibrosis — fewer than ten, so there is no comparison to draw.
2 of the studies testing pacritinib in Primary Myelofibrosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06414681University of Kansas Medical CenterCombination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined | 2026-12 |
| NCT04282187University of WashingtonDecitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | 2027-11-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies testing pacritinib in Primary Myelofibrosis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was an open-label, randomized, dose-finding study in patients with primary or secondary MF (Dynamic International Prognostic Scoring System [DIPSS] risk score of Intermediate-1 to High-Risk) who were previously treated with ruxolitinib. The study was designed to support a pacritinib dosage selection decision with evaluation of 3 dosages.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Prior ruxolitinib treatment with failure to benefit or intolerance as defined by at least one of the following:
i. Development of a red blood cell (RBC) transfusion requirement (at least 2 units/month for 2 months) ii. National Cancer Institute (NCI) grade ≥3 AEs of thrombocytopenia, anemia, hematoma, and/or hemorrhage while being treated with a dosage of \<20 mg BID
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pacritinib
Drug: Pacritinib
Drug: Pacritinib
Pacritinib
Spleen Volume Reduction Response (≥ 35%)
Number of patients achieving a ≥ 35% spleen volume reduction (SVR) as measured by magnetic resonance imaging (MRI, preferred) or computed tomography (CT) scans
Time frame: From Baseline to Weeks 12 and 24
Percent Change in Spleen Volume
Percent change from baseline
Time frame: From Baseline to Weeks 12 and 24
Total Symptom Score Analysis
Proportion of patients with ≥ 50% reduction in Total Symptom Score from baseline as assessed by the validated PRO instrument MPN-SAF TSS 2.0
Time frame: From Baseline to Weeks 12 and 24
Patient Global Impression Assessment
Number of patients with improvement in PGIA. The Patient Global Impression Assessment questionnaire was completed at the end of Week 12 and end of Week 24. The scores were summarized by treatment group at each visit.
Time frame: From Baseline to Weeks 12 and 24
Spleen Length Reduction
Rate of reduction in spleen length from baseline
Time frame: From Baseline to Weeks 24
Frequency of RBC's or Platelet Transfusions
Number of patients
Time frame: At week 24
Eastern Cooperative Oncology Group Performance Status
0 = Fully active, able to carry on all pre-disease performance without restriction 1. = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work 2. = Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours 3. = Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours 4. = Completely disabled; cannot carry on any selfcare; totally confined to bed or chair 5. = Dead
Time frame: At weeks 4, 12, 24, and 30 days post End-of-Treatment visit
Number of Participants With Adverse Events
Time frame: Randomization through 30 days post End-of-Treatment visit
| Milestone | Pacritinib 100 mg QD | Pacritinib 100 mg BID | Pacritinib 200 mg BID |
|---|---|---|---|
| Started | 55 | 55 | 55 |
| Completed | 52 | 55 | 54 |
| Not completed | 3 | 0 | 1 |
Number of patients achieving a ≥ 35% spleen volume reduction (SVR) as measured by magnetic resonance imaging (MRI, preferred) or computed tomography (CT) scans
| Participants | Pacritinib 100 mg QD | Pacritinib 100 mg BID | Pacritinib 200 mg BID |
|---|---|---|---|
| End of Week 12 | 0 | 2 | 2 |
| End of Week 24 | 0 | 1 | 5 |
Percent change from baseline
| percent change from baseline | Pacritinib 100 mg QD | Pacritinib 100 mg BID | Pacritinib 200 mg BID |
|---|---|---|---|
| Week 12 | 3.19 ± 22.613 | 6.37 ± 31.110 | -3.60 ± 26.610 |
| Week 24 | -2.43 ± 17.608 | 0.65 ± 20.589 | -11.30 ± 26.417 |
Proportion of patients with ≥ 50% reduction in Total Symptom Score from baseline as assessed by the validated PRO instrument MPN-SAF TSS 2.0
| Participants | Pacritinib 100 mg QD | Pacritinib 100 mg BID | Pacritinib 200 mg BID |
|---|---|---|---|
| End of Week 12 | 1 | 1 | 2 |
| End of Week 24 | 2 | 0 | 2 |
Number of patients with improvement in PGIA. The Patient Global Impression Assessment questionnaire was completed at the end of Week 12 and end of Week 24. The scores were summarized by treatment group at each visit.
| Participants | Pacritinib 100 mg QD | Pacritinib 100 mg BID | Pacritinib 200 mg BID |
|---|---|---|---|
| Week 12 - Any Improved | 17 | 21 | 23 |
| Week 12 -No Change | 6 | 5 | 8 |
| Week 12 -Any Worse | 8 | 8 | 3 |
| Week 24 - Any Improved | 10 | 13 | 18 |
| Week 24 -No Change | 6 | 5 | 1 |
| Week 24 -Any Worse | 5 | 3 | 2 |
Rate of reduction in spleen length from baseline
| cm | Pacritinib 100 mg QD | Pacritinib 100 mg BID | Pacritinib 200 mg BID |
|---|---|---|---|
| Spleen Length Reduction | 12.42 ± 5.602 | 11.48 ± 6.501 | 11.63 ± 7.131 |
Number of patients
| transfusions/month | Pacritinib 100 mg QD | Pacritinib 100 mg BID | Pacritinib 200 mg BID |
|---|---|---|---|
| Frequency of RBC's or Platelet Transfusions | 2.27 ± 2.987 | 1.18 ± 2.553 | 2.25 ± 2.345 |
0 = Fully active, able to carry on all pre-disease performance without restriction 1. = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work 2. = Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours 3. = Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours 4. = Completely disabled; cannot carry on any selfcare; totally confined to bed or chair 5. = Dead
| Participants | Pacritinib 100 mg QD | Pacritinib 100 mg BID | Pacritinib 200 mg BID |
|---|---|---|---|
| Week 4 - 0 | 10 | 11 | 13 |
| Week 4 - 1 | 28 | 27 | 31 |
| Week 4 - 2 | 9 | 16 | 8 |
| Week 4 - 3 | 2 | 0 | 0 |
| Week 4 - 4 | 0 | 0 | 0 |
| Week 4 - 5 | 0 | 0 | 0 |
| Week 12 - 0 | 11 | 9 | 14 |
| Week 12 - 1 | 20 | 23 | 19 |
| Week 12 - 2 | 8 | 10 | 8 |
| Week 12 - 3 | 1 | 1 | 2 |
| Week 12 - 4 | 0 | 0 | 0 |
| Week 12 - 5 | 0 | 0 | 0 |
| Week 24 - 0 | 10 | 6 | 10 |
| Week 24 - 1 | 12 | 15 | 12 |
| Week 24 - 2 | 4 | 5 | 6 |
| Week 24 - 3 | 0 | 0 | 0 |
| Week 24 - 4 | 0 | 0 | 0 |
| Week 24 - 5 | 0 | 0 | 0 |
| End of Treatment - 0 | 11 | 8 | 8 |
| End of Treatment - 1 | 19 | 23 | 22 |
| End of Treatment - 2 | 5 | 10 | 11 |
| End of Treatment - 3 | 1 | 1 | 2 |
| End of Treatment - 4 | 0 | 0 | 0 |
| End of Treatment - 5 | 0 | 0 | 0 |
| Participants | Pacritinib 100 mg QD | Pacritinib 100 mg BID | Pacritinib 200 mg BID |
|---|---|---|---|
| Number of Participants With Adverse Events | 49 | 51 | 54 |
Collected over The end of assigned study drug + 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pacritinib 100 mg QD | 6/52 (11.5%) | 19/52 (36.5%) | 24/52 (46.2%) |
| Pacritinib 100 mg BID | 4/55 (7.3%) | 20/55 (36.4%) | 34/55 (61.8%) |
| Pacritinib 200 mg BID | 5/54 (9.3%) | 25/54 (46.3%) | 36/54 (66.7%) |
| Event | Pacritinib 100 mg QD | Pacritinib 100 mg BID | Pacritinib 200 mg BID |
|---|---|---|---|
| PneumoniaInfections and infestations | 2/52 | 2/55 | 5/54 |
| PyrexiaGeneral disorders | 3/52 | 2/55 | 3/54 |
| DehydrationMetabolism and nutrition disorders | 0/52 | 3/55 | 2/54 |
| General physical health deteriorationGeneral disorders | 2/52 | 0/55 | 0/54 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/52 | 0/55 | 0/54 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/52 | 0/55 | 2/54 |
| SepsisInfections and infestations | 1/52 | 1/55 | 2/54 |
| Clostridium difficile colitisInfections and infestations | 0/52 | 1/55 | 2/54 |
| GastroenteritisInfections and infestations | 0/52 | 1/55 | 2/54 |
| Renal failure acuteRenal and urinary disorders | 1/52 | 0/55 | 2/54 |
| Event | Pacritinib 100 mg QD | Pacritinib 100 mg BID | Pacritinib 200 mg BID |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 6/52 | 8/55 | 14/54 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/52 | 5/55 | 9/54 |
| NauseaGastrointestinal disorders | 7/52 | 7/55 | 3/54 |
| FatigueGeneral disorders | 1/52 | 7/55 | 5/54 |
| AnaemiaBlood and lymphatic system disorders | 1/52 | 3/55 | 6/54 |
| Decreased appetiteMetabolism and nutrition disorders | 3/52 | 2/55 | 3/54 |
| BronchitisInfections and infestations | 3/52 | 1/55 | 1/54 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/52 | 1/55 | 3/54 |
| Ejection fraction decreasedInvestigations | 1/52 | 3/55 | 2/54 |
| PyrexiaGeneral disorders | 1/52 | 3/55 | 1/54 |
| Age, Categorical(Participants) | Pacritinib 100 mg QD | Pacritinib 100 mg BID | Pacritinib 200 mg BID | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 16 | 11 | 16 | 43 |
| >=65 years | 36 | 44 | 38 | 118 |
| Age, Continuous(years) | Pacritinib 100 mg QD | Pacritinib 100 mg BID | Pacritinib 200 mg BID | Total |
|---|---|---|---|---|
| Mean | 69 ± 8.8 | 68.9 ± 6.9 | 68.1 ± 8.76 | 68.7 ± 8.14 |
| Sex: Female, Male(Participants) | Pacritinib 100 mg QD | Pacritinib 100 mg BID | Pacritinib 200 mg BID | Total |
|---|---|---|---|---|
| Female | 21 | 26 | 22 | 69 |
| Male | 31 | 29 | 32 | 92 |
| Race (NIH/OMB)(Participants) | Pacritinib 100 mg QD | Pacritinib 100 mg BID | Pacritinib 200 mg BID | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 2 | 1 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 4 | 5 |
| White | 44 | 47 | 48 | 139 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 5 | 7 | 0 | 12 |
| BMI(kg/m^2) | Pacritinib 100 mg QD | Pacritinib 100 mg BID | Pacritinib 200 mg BID | Total |
|---|---|---|---|---|
| Mean | 25.1 ± 3.79 | 27.2 ± 4.11 | 26.4 ± 5 | 26.3 ± 4.4 |
| ECOG PS(participants) | Pacritinib 100 mg QD | Pacritinib 100 mg BID | Pacritinib 200 mg BID | Total |
|---|---|---|---|---|
| 0 | 11 | 14 | 17 | 42 |
| 1 | 32 | 29 | 29 | 90 |
| 2 | 9 | 12 | 8 | 29 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2017 to primary completion in Sep 2019, 25 months.
Results were first posted in Jun 2022, 2 years 8 months after primary completion.
Of 30 industry-sponsored phase 2 interventional studies under Primary Myelofibrosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 66. This study's 25 months is below that.
Counting every sponsor, half of 98 studies reached it within 66 months; a quarter within 32 and three quarters within 111.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pacritinib